ClinicalTrials.Veeva

Menu

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim logo

Boehringer Ingelheim

Status and phase

Completed
Phase 3

Conditions

Pulmonary Disease, Chronic Obstructive

Treatments

Drug: Olodaterol (BI1744) Low
Drug: Placebo (for Tiotropium)
Drug: Olodaterol (BI1744) High
Drug: Placebo (for Olodaterol (BI1744)l)
Drug: Tiotropium 18 mcg

Study type

Interventional

Funder types

Industry

Identifiers

NCT01040728
2009-014418-86 (EudraCT Number)
1222.40

Details and patient eligibility

About

The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Enrollment

122 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients willing to participate with confirmed diagnosis of COPD
  • 40 years of age or older
  • having a 10 pack year smoking history
  • able to perform serial pulmonary function tests
  • able to use both a Dry powder inhaler (DPI) and Respimat device

Exclusion criteria

  • Significant other disease
  • clinically relevant abnormal hematology, chemistry, or urinalysis
  • history of asthma
  • diagnosis of thyrotoxicosis
  • paroxysmal tachycardia related to beta agonists
  • history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year
  • active tuberculosis, cystic fibrosis, clinically evident bronchiectasis
  • significant alcohol or drug abuse
  • pulmonary resection
  • taking oral beta adrenergics
  • taking unstable oral steroids
  • daytime oxygen
  • enrolled in rehabilitation program
  • enrolled in another study or taking investigational products
  • pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control
  • those who are not willing to comply with pulmonary medication washouts

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

122 participants in 4 patient groups, including a placebo group

Olodaterol (BI1744) Low
Experimental group
Description:
Low dose inhaled orally once daily from Respimat inhaler
Treatment:
Drug: Olodaterol (BI1744) Low
Olodaterol (BI1744) High
Experimental group
Description:
High dose inhaled orally once daily from Respimat inhaler
Treatment:
Drug: Olodaterol (BI1744) High
Tiotropium 18 mcg
Active Comparator group
Description:
18 mcg inhaled once daily from HandiHaler
Treatment:
Drug: Tiotropium 18 mcg
Placebo
Placebo Comparator group
Description:
Olodaterol placebo and/or Tiotropium placebo inhaled once daily
Treatment:
Drug: Placebo (for Tiotropium)
Drug: Placebo (for Olodaterol (BI1744)l)

Trial contacts and locations

12

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems